Is Biodexa Pharmaceuticals Plc (BDRX) a Buy, Sell, or Hold?
Biodexa Pharmaceuticals Plc
NASDAQ:BDRX
$2.27 USD
-$0.04 (-1.73%)
- Volume
- 16.96K
- Average Volume
- 407.65K
- Market Capitalization
- $1.69M
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $59.40
- Year Low
- $2.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.03
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Stephen Anthony Stamp |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BDRX |
| CUSIP | 59564R872 |
| CIK | 0001643918 |
| Web | https://www.biodexapharma.com |
| Phone | 44 29 2048 0180 |
| Currency | USD |
| Employees | 11 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.03 |
| Quick Ratio | 2.03 |
| Cash Ratio | 1.39 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -62.35 |
| Price / Cash Flow | -0.22 |
| Price / Book | 0.01 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-400 |
| Trailing P/E Ratio | 0.00 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-6.24M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -55.81% |
| Return on Assets | -35.09% |
Financials Score
| AltmanZ Score | -10.48 |
| Piotroski Score | 2.00 |
| Working Capital | 6.3M |
| Total Assets | 18.15M |
| Ebit | -17.1M |
| Market Cap | 1.44M |
| Total Liabilities | 6.76M |
Poll Results
About Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Stock
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as a ... n investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Result of Annual General Meeting
2026-06-30 16:30:00
June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers announces that its re-scheduled Annual General Meeting held at 11.00 BST today, ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, respectively. Ordinary resolution 8 and special resolution 10 failed to pass.
2026-06-30 08:00:00
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a $0.8 million registered offering (the “Registered Offering”), a $1.0 million concurrent private placement (the “Private Offering”) and a $1.7 million warrant inducement (the “Warrant Inducement” and, together with the Registered Offering and the Private Offering, the “Offerings”) utilizing existing share capital authorities. The Registered Offering consists of 282,952 American depositary shares (“ADSs”) (or pre-funded warrants in lieu thereof) at an offering price of $2.85 per ADS.
2026-06-29 08:30:00
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has received approval from Health Canada to expand its registrational Phase 3 trial in familial adenomatous polyposis (“FAP”) into Canada. The Phase 3 study, branded Serenta, is already up and running in a total of 29 active recruiting clinical centers spread across the US and five countries in Europe.
Postponement and Re-scheduling of Annual General Meeting
2026-06-17 16:30:00
June 17, 2026 Biodexa Pharmaceuticals PLC Postponement and Re-scheduling of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that its Annual General Meeting (“AGM”) scheduled for 11.00am BST today was adjourned due to lack of a quorum. In accordance with the Company's articles of association, the AGM cannot be reconvened for 10 clear days.
Biodexa issues letter to Shareholders
2026-05-14 08:30:00
May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company's share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder's rights.
Frequently Asked Questions
-
What is the current Biodexa Pharmaceuticals Plc (BDRX) stock price?
-
Biodexa Pharmaceuticals Plc(NASDAQ:BDRX) stock price is $2.27 in the last trading session. During the trading session, BDRX stock reached the peak price of $59.4 while $2.1 was the lowest point it dropped to. The percentage change in BDRX stock occurred in the recent session was --1.73% while the dollar amount for the price change in BDRX stock was -$-0.04.
-
BDRX's industry and sector of operation?
-
The NASDAQ listed BDRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BDRX?
-
Gary A. Shangold FACOG | Chief Medical Officer
Stephen A. Stamp | CEO & Director
Fiona Mary Powell | Company Secretary, CFO & Director
Noreen Bhatti | Vice President of Clinical Operations
Daniel Palmer | Vice President of Technology -
How many employees does BDRX have?
-
Number of BDRX employees currently stands at 11. BDRX operates from 1 Caspian Point, Cardiff, WA CF10 4DQ, GB.
-
Link for BDRX official website?
-
Official Website of BDRX is: https://www.biodexapharma.com
-
How do I contact BDRX?
-
BDRX could be contacted at phone #44 29 2048 0180 and can also be accessed through its website. BDRX operates from 1 Caspian Point, Cardiff, WA CF10 4DQ, GB.
-
How many shares of BDRX are traded daily?
-
The average number of BDRX shares traded daily for last 3 months was 407.65K.
-
What is the market cap of BDRX currently?
-
The market value of BDRX currently stands at $1.69M with its latest stock price at $2.27